Various studies demonstrated LSD1 contribution to the onset and progression of acute myeloid leukemia (AML), indicating that this enzyme can be a therapeutic target for the treatment of different AML subtypes [12, 18–20]. Here, KDM1A is linked to acute myeloid leukemia.